Fireside Chat Webinar
Fireside Chat Webinar
Hosted Live | 7 Feb 2023
Bob Proulx, Imagion’s CEO, and Dr. Yalia Jayalakshmi, Chief Development Officer discussed the latest positive independent review of our MagSense® HER2 imaging agent including what this means for Imagion Biosystems; how this accelerates our path to market; an update on the future of our technology; and fielded questions from attendees in a Q&A session.
Questions? Email us: investor@imagionbio.com
Interested to learn more information about our independent review and path to market?
Read More of Our Latest News
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
2023 AGM Resolution Overview
Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting
Imagion initiates leadership restructuring plan
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.